摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-[2-(3,5-Dichloro-N-oxo-pyridin-4-yl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocine

中文名称
——
中文别名
——
英文名称
7-[2-(3,5-Dichloro-N-oxo-pyridin-4-yl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocine
英文别名
7-[2-(3,5-dichloro-N-oxo-pyridin-4-yl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocin;7-[2-(3,5-Dichloro-N-oxo-4-pyridyl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocine;7-[2-(3,5-dichloro-N-oxo-4-pyridyl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocin;7-[2-(3,5-dichloro-N-oxo-4-pyridyl)-1-oxoethyl]-10methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocin;2-(3,5-Dichloro-1-oxidopyridin-1-ium-4-yl)-1-(7-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocin-10-yl)ethanone
7-[2-(3,5-Dichloro-N-oxo-pyridin-4-yl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocine化学式
CAS
——
化学式
C18H17Cl2NO5
mdl
——
分子量
398.243
InChiKey
SSEUSLAMKWTKIT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    70.2
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE
    申请人:——
    公开号:US20020128290A1
    公开(公告)日:2002-09-12
    An oxygen-containing heterocyclic compound represented by following Formula (I): 1 wherein R 1 and R 2 independently represent hydrogen, lower alkyl, cyano, —(CH 2 ) n —E 1 —CO—G 1 (wherein E 1 represents a bond, O, or NH; and G 1 represents hydrogen, substituted or unsubstituted lower alkyl, OR 6 , or NR 7 R 8 ; and n represents an integer of 0 to 4), or the like; R 1 and R 2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R 2 , and R 11 or R 13 described below are combined to form a single bond; R 3 represents hydrogen, phenyl, or halogen; R 4 represents hydroxy, lower alkoxy, or the like; A represents —C(R 9 )(R 10 )— or O; B represents O, NR 11 , —C(R 12 )(R 13 )—, or —C(R 14 )(R 15 )—C(R 16 )(R 17 )—; D represents (i) —C(R 18 )(R 19 )—X— (wherein X represents —C(R 21 )(R 22 )—, S, or NR 23 ), (ii) —C(R 19a )═Y— [Y represents —C(R 24 )—Z— (wherein Z represents CONH, CONHCH 2 , or a bond), or N], or (iii) a bond; and R 5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.
    以下是由下式(I)表示的含氧杂环化合物: 其中R1和R2独立地表示氢、较低的烷基、基、—(CH2)n—E1—CO—G1(其中E1表示键、O或NH;G1表示氢、取代或未取代的较低烷基、OR6或NR7R8;n表示0到4的整数),或类似物;R1和R2结合表示与相邻碳原子一起形成饱和碳环;或R2,以及下文描述的R11或R13结合形成单键;R3表示氢、苯基或卤素;R4表示羟基、较低的烷氧基或类似物;A表示—C(R9)(R10)—或O;B表示O、NR11、—C(R12)(R13)—或—C(R14)(R15)—C(R16)(R17)—;D表示(i)—C(R18)(R19)—X—(其中X表示—C(R21)(R22)—、S或NR23)、(ii)—C(R19a)═Y—[Y表示—C(R24)—Z—(其中Z表示CONH、CONH 或键),或N],或(iii)键;R5表示芳基、芳香杂环基、环烷基、吡啶-N-氧化物基或较低烷氧羰基;或其药学上可接受的盐。
  • ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES
    申请人:Marfat Anthony
    公开号:US20070161681A1
    公开(公告)日:2007-07-12
    Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein the substituents are as defined in the specification.
    以下化合物可用作PDE4的抑制剂,用于治疗由嗜酸性粒细胞的活化和脱颗粒调控的疾病,特别是哮喘、慢性支气管炎和慢性阻塞性肺疾病,其化学式如下:其中取代基如规范中所定义。
  • OXYGENIC HETEROCYCLIC COMPOUNDS
    申请人:KYOWA HAKKO KOGYO KABUSHIKI KAISHA
    公开号:EP0943613A1
    公开(公告)日:1999-09-22
    Oxygen-containing heterocyclic compounds represented by following Formula (I): wherein n represents an integer of 1 to 4; R1, R2, R3 and R4 are the same or different and represent hydrogen, substituted or unsubstituted lower alkyl, or the like; R5 represents hydrogen or halogen; R6 represents hydroxy or substituted or unsubstituted lower alkoxy; D represents (1) -C(R8)(R9)-X- or (2) a bond; R7 represents (1) substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, polycycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heterocyclic group, or pyridine-N-oxide, (2) -Y-ZR14, (3) -Y-Z-(CH2)m-N(R16a)R16b, or (4) -Y-CON(R17a)R17b, or pharmaceutically acceptable salts thereof.
    下式(I)所代表的含氧杂环化合物: 其中 n 代表 1 至 4 的整数;R1、R2、R3 和 R4 相同或不同,代表氢、取代或未取代的低级烷基或类似物; R5 代表氢或卤素;R6 代表羟基或取代或未取代的低级烷氧基;D 代表 (1) -C(R8)(R9)-X- 或 (2) 键;R7 代表 (1) 取代或未取代的低级烷基、取代或未取代的环烷基、多环烷基、取代或 未取代的芳基、取代或未取代的芳烷基、(2) -Y-ZR14, (3) -Y-Z-(CH2)m-N(R16a)R16b, 或 (4) -Y-CON(R17a)R17b, 或其药学上可接受的盐。
  • US6514996B2
    申请人:——
    公开号:US6514996B2
    公开(公告)日:2003-02-04
  • US6716987B1
    申请人:——
    公开号:US6716987B1
    公开(公告)日:2004-04-06
查看更多

同类化合物

胰岛素原(cattle),29-[N6-[[2-(甲磺酰)乙氧基]羰基]-L-赖氨酸]-59-[N6-[[2-(甲磺酰)乙氧基]羰基]-L-赖氨酸]-(9CI) 十氢-2,7-苯并二氧杂环癸烷-3,6-二酮 二环<3.3.0>-2-氧杂-5-(2-丙烯基)-1-辛烯 乙烯邻苯二甲酸酯 [(E,1R)-1-[(2R,4Z,7S,8R)-7-溴-8-乙基-3,6,7,8-四氢-2H-氧杂环辛三烯-2-基]己-3-烯-5-炔基]乙酸酯 [(2R,3S,4E,6R,7S)-6,7-二羟基-2-甲基-10-氧代-2,3,6,7,8,9-六氢氧杂环辛三烯-3-基] (E)-丁-2-烯酸酯 6,7-二氢-5aH-氧杂环丁烷并[3,2-d][1,3]苯并二氧戊环 5-氧杂-10-氮杂三环[5.3.1.03,8]十一碳-1(10),2,6,8-四烯 3-氧杂二环[3.3.1]壬-6-烯-9-酮 3,4,5,6-四氢-2,7-苯并二氧杂环癸烷e-1,8-二酮 17-苯基-18,19,20-三去甲-前列腺素F2-alpha1,15-内酯 10-(乙酰氧基)-4,5,6,7-四氢-2H-1-苯并氧杂环辛三烯-2,8(3H)-二酮 1-(2,3,4,5-四氢-1,6-苯并二噁辛英-8-基)丙烷-1-酮 1,2-环己烷二甲酸1-甲基-1,2-乙二基酯 (S)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 (R)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 (7Z)-2-(3-溴丙-1,2-二烯基)-5-(1-溴丙基)-3,3a,5,6,9,9a-六氢-2H-呋喃并[3,2-b]氧杂环辛三烯 (7E)-4,7-二羟基-10-甲基-3,4,5,6,9,10-六氢氧杂环辛三烯-2-酮 (6Z)-10-甲基-3,4,5,8,9,10-六氢-2H-氧杂环辛三烯-2-酮 (5Z,8S)-3-氯-2-[(E)-戊-2-烯-4-炔基]-8-[(E)-丙-1-烯基]-3,4,7,8-四氢-2H-氧杂环辛三烯 (4Z)-3,6-二氢-2,7-苯并二氧杂环癸烷e-1,8-二酮 (4S,5Z,7S,8S,10R)-4,7,8-三羟基-10-甲基-3,4,7,8,9,10-六氢氧杂环辛三烯-2-酮 (4R,5R,6Z,8S,10R)-4,5,8-三羟基-10-甲基-3,4,5,8,9,10-六氢氧杂环辛三烯-2-酮 (2R,5Z)-8a-[(R)-1-溴丙基]-3a-氯-3,4,7,8-四氢-2a-[(Z)-2-戊烯-4-炔基]-2H-氧杂环辛三烯 8-Chlor-1,6-benzodioxocin 2,2,6-Trifluoro-4-phenyl-3-trifluoromethyl-2H-pyran 2,3,4,5,6,7-Hexahydro-1-benzoxonin aspinolide C 4-deutero-4,5-dihydro-2H-benzo[b]oxocin-6(3H)-one 3-Carbethoxy-4-bromo-5,6-dihydro-2-pyron (E,8S,13S)-8,13-diisopropyl-5,8,9,12,13,16-hexahydro-6,15-dioxa-benzocyclotetradecene-7,14-dione (1S,7Z,10R,11S)-11-t-butyldimethylsolyloxy-4-oxabicyclo[8.3.0]tridec-7-en-3-one (Z)-2-Methyl-3a,4,5,6,7,9a-hexahydro-cycloocta[b]furan-3-carboxylic acid ethyl ester (5R,8S,9R,10S,E)-5,8,9-trihydroxy-10-methyl-3,4,5,8,9,10-hexahydro-2H-oxecin-2-one 19,21-Dimethyl-4,15-dioxa-bicyclo[16.2.2]docosa-1(21),18(22),19-triene-3,16-dione (1S,4aR,8aS)-1,4,4a,8a-Tetrahydro-naphthalen-1-ol 5-methyl-2-oxo-2H-cyclohepta[b]furan-3-carboxylic acid methyl ester trans,trans-2,3;10,11-Dibenzo-1,4,9,12-tetraoxa-cyclohexadecatetraen-(2,6,10,14) 1-C-(4-O-acetyl-2,3,6-trideoxy-β-L-erytro-hex-2-en-pyranosyl)-3-bromopentane 2,2,2-Trichloro-acetimidic acid (2S,3S,6R)-2-methoxy-6-methyl-3,6-dihydro-2H-pyran-3-yl ester 1-C-(4-O-acetyl-2,3,6-trideoxy-α-L-erytro-hex-2-en-pyranosyl)-5-bromopentane (3,4-dihydro-1H-2-benzopyran-7-yl)methanesulfonylchloride methyl 2,3-C-(2-butene-1,4-diyl)-2,3-dideoxy-α,β-D-talofuranoside 3-oxobicyclo<7.3.1>-trideca-1(12),9(10)-diene-(ZZ)-12-carboxylic acid (3aS,5S,6R,8aR)-6-Hydroxy-5-methyl-3,3a,4,5,6,8a-hexahydro-cyclohepta[b]furan-2-one (Z)-3-butyl-6,7,8,9-tetrahydrooxonin-2(5H)-one 3,6-dihydro-4-methyl-2H-1-benzoxocine 18,20-Dimethyl-4,14-dioxa-bicyclo[15.2.2]henicosa-1(20),17(21),18-triene-3,15-dione 3-butyl-5,6,7,8,9,10-hexahydro-2H-oxecin-2-one